Align Technology Reports Strong Q4 Earnings Beat
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Should l Buy ALGN?
Source: Benzinga
- Earnings Beat: Align Technology reported Q4 earnings of $3.29 per share, surpassing analyst expectations of $2.97, indicating a significant improvement in profitability and boosting market confidence in future growth.
- Sales Growth: The company achieved quarterly sales of $1.047 billion, exceeding the consensus estimate of $1.033 billion, demonstrating robust performance amid strong market demand.
- Stock Surge: Align's shares jumped 10.4% in pre-market trading to $178.13, reflecting a positive investor reaction to the financial results, which may attract more investor interest.
- Increased Market Confidence: This earnings beat not only enhances Align's market image but also potentially supports its future investment and expansion plans, further solidifying its leadership position in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALGN
Wall Street analysts forecast ALGN stock price to rise
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 176.250
Low
169.00
Averages
198.70
High
220.00
Current: 176.250
Low
169.00
Averages
198.70
High
220.00
About ALGN
Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Shareholder Engagement: Elliott Investment Management has become one of Align Technology's largest shareholders and plans to engage with the company to encourage strategies for boosting its stock price, indicating a proactive interest in the company's future development.
- Stock Performance: Align Technology's stock has plummeted 75% since its record high in September 2021; however, shares jumped 4% in premarket trading following news of Elliott's investment, reflecting a market reassessment of its future potential.
- Analyst Ratings: According to Koyfin, 11 out of 17 analysts recommend a ‘Buy’ or higher for Align's stock, projecting an average upside of 17% over the next 12 months, demonstrating confidence in the company's international expansion and continued adoption of its Invisalign products.
- Market Sentiment Shift: On the Stocktwits platform, retail investor sentiment for Align has shifted from ‘neutral’ at the beginning of the week to ‘bullish’, indicating a growing optimism among investors regarding the company's future performance.
See More
- Market Decline: On Thursday, the S&P 500 fell by 0.27%, the Dow Jones Industrial Average by 0.44%, and the Nasdaq 100 by 0.29%, indicating a broad market decline driven by inflation concerns and investor pessimism.
- Energy Price Volatility: Crude oil prices experienced significant fluctuations as WTI initially rallied before retreating after Israel's assistance to the US in opening the Strait of Hormuz, highlighting the direct impact of geopolitical tensions on energy markets.
- Rising Bond Yields: The 10-year German Bund yield rose to a 2.25-year high of 3.01%, while the 10-year US Treasury yield reached a 6.75-month high of 4.32%, reflecting market expectations of potential tightening monetary policies by central banks, which could increase borrowing costs.
- Economic Data Impact: US weekly initial jobless claims unexpectedly fell to 205,000, indicating a strong labor market, while the Philadelphia Fed business outlook survey unexpectedly rose to a 6-month high of 18.1, further intensifying market concerns over potential interest rate hikes.
See More
- Investor Stake Increase: Elliott Investment Management has become one of Align Technology's largest investors, indicating a strategic intent to push for stock price improvement and potentially engage with management to explore options for enhancing share value.
- Stock Price Decline: Align's stock has sharply fallen from its 2021 peak of $729.92 to a recent close of $172.41, reflecting a market value of approximately $12.3 billion, which highlights a significant drop in demand following a surge in cosmetic dental treatments during the pandemic.
- Signs of Market Stabilization: Barclays analysts noted in a February 4 report that dental markets may be finding a floor this year, suggesting that Align could recover some lost valuation, with potential trading closer to 12 times EBITDA compared to around 10 times currently, indicating possible upside.
- Historical Valuation Comparison: Although Align's valuation remains below historical averages of 17 and 21 times over three- and five-year periods, respectively, improving market conditions could yield higher returns for investors, particularly as factors related to its Israel manufacturing operations evolve.
See More
- Market Decline: The S&P 500 index fell by 0.43%, the Dow Jones Industrial Average by 0.59%, and the Nasdaq 100 by 0.44%, indicating a broad sell-off in global equities driven by inflation concerns and investor pessimism.
- Rising Bond Yields: Hawkish comments from the BOE, ECB, and BOJ pushed global bond yields higher, with the 10-year German Bund yield reaching a 2.25-year high of 3.01%, which will increase borrowing costs and impact corporate financing.
- Surging Energy Prices: European natural gas prices surged over 12% to a three-year high due to escalating conflict in Iran, with Qatar reporting a 17% damage to its LNG export capacity, raising inflation risks and potentially disrupting global energy supplies.
- Strong US Economic Data: Despite initial jobless claims unexpectedly falling to 205,000, indicating a robust labor market, January new home sales plummeted 17.6% to 587,000, below expectations, reflecting weakness in the housing market that may affect future economic growth.
See More
- Healthcare Index Decline: The NYSE Health Care Index fell by 0.4% on Thursday afternoon, indicating a decline in overall market confidence in the healthcare sector, which may influence investors' decisions regarding stock holdings.
- Market Sentiment Weakens: The drop in healthcare stocks may be linked to broader economic uncertainties, as investor concerns about future economic growth intensify, leading to capital outflows from the healthcare sector and impacting its short-term performance.
- Investor Reactions: As healthcare stocks decline, investors may reassess their portfolios, considering reallocating funds to other sectors that are performing better to mitigate risk and seek higher returns.
- Uncertain Industry Outlook: The future performance of the healthcare sector may be influenced by policy changes and market dynamics, prompting investors to closely monitor relevant policy developments to adjust their investment strategies accordingly.
See More
- Oil Price Surge Impact: Stocks fell as Brent crude briefly hit $119 per barrel following Iran's attack on a key LNG facility in Qatar, causing the S&P 500 to slip below its 200-day moving average for the first time since last May, raising concerns among long-term investors.
- Eli Lilly Drug Study Update: Eli Lilly reported that its Phase 3 study of retatrutide for type 2 diabetes showed superior weight loss compared to Mounjaro over 40 weeks, yet the stock remained stagnant as investors are more focused on the anticipated approval of its new GLP-1 pill next month.
- Nvidia Stock Analysis: Jim Cramer reiterated his
See More











